Oxandrolone is a 17-alpha-alkylated oral anabolic steroid. Oxandrolone has an excellent myotrophic activity index of 3.2 and a low androgenic activity index of 0.2. At low doses, oxandrolone will not cause suppression of endogenous testosterone production and does not aromatize to estrogens.
Oxandrolone was approved for treating alcoholic hepatitis, Turner’s syndrome, and weight loss caused by HIV. In addition, the drug has shown positive results in treating anemia and hereditary angioedema and for preserving muscle mass in burns patients. Oxandronolne also has been used with good success for idiopathic muscle mass loss and osteoporosis. At low dose (5-10mg), oxandrolone binds weakly to androgen receptors and therefore can be used by woman and does not cause virilisation. Oxandrolone has a half life 10-13 hours.
|each tablet contains:|
Packing: 100 tablets in a Glass Vial
Dosage and administration
Geriatric use: at daily doses of 5- 10 mg proved to be safe for up 4 months of continuous use.
Hepatic: Cholestatic jaundice. Hepatocellular neoplasms and peliosis hepatis with long-term therapy. Reversible changes in liver function tests also occur. In females: Clitoral enlargement, menstrual irregularities.
Anabolic steroids may increase sensitivity to oral anticoagulants. Dosage of the anticoagulant may have to be decreased in order to maintain desired prothrombin time. Patients receiving oral anticoagulant therapy require close monitoring, especially when anabolic steroids are started or stopped.
Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.
Known or suspected carcinoma of the prostate or the male breast.
Carcinoma of the breast in females with hypercalcemia (androgenic anabolic steroids may stimulate osteolytic bone resorption). Pregnancy.